HCA Healthcare Gets Price Target Bumps By Analysts After Upbeat Q1 Results

HCA Healthcare HCA reported better-than-expected Q1 results and revised FY23 guidance.

HCA Healthcare reported Q1 FY23 revenues of $15.59 billion, compared to $14.94 billion a year ago, missing the consensus of $15.27 billion. EPS of $4.93 was higher than the $4.12 reported a year ago, surpassing the estimate of $3.93.

For FY23, HCA Healthcare raised revenues guidance to $62.5-$64.5 billion from $61.5-63.5 billion compared to the consensus Of $62.61 billion.

HCA Healthcare shares gained 3.9% to close at $281.21 on Friday, and added 0.1% in today’s pre-market trading session.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

• Citigroup raised the price target on HCA Healthcare from $293 to $324. Citigroup analyst Jason Cassorla maintained a Buy rating.
• Oppenheimer increased the price target on HCA Healthcare from $270 to $310. Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating
• Credit Suisse increased the price target on HCA Healthcare from $282 to $311. Credit Suisse analyst A.J. Rice maintained the stock with an Outperform.

Read More: $59M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying